In line with the in vitro results, in vivo assay using a pancreatic tumor mouse model with IP injected AsPC-1 cells also demonstrated the stronger anti-tumor activity of ACOD1-/- MSLN-CAR-iMACs (Supplementary Fig. 12e–h). This evidence concerns the gene MSLN and neoplasm.